Skip to main content
Clinical Trials/TCTR20230719005
TCTR20230719005
Recruiting
Phase 3

The effectiveness of levofloxacin in prevention of febrile episodes in non-Hodgkin lymphoma patients receiving R-CHOP

Ratchadapisek Research Funds0 sites72 target enrollmentJuly 19, 2023

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Febrile episode in non-Hodgkin lymphoma
Sponsor
Ratchadapisek Research Funds
Enrollment
72
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 19, 2023
End Date
June 30, 2024
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Ratchadapisek Research Funds

Eligibility Criteria

Inclusion Criteria

  • Non\-Hodgkin lymphoma patients confirmed by pathology
  • Age 18 years old or more
  • Receive R\-CHOP regimen

Exclusion Criteria

  • Refuse to treatment/not consent
  • History of fluoroquinolone allergy
  • QT prolongation on ECG
  • History of serious adverse events from fluoroquinolone
  • unable to follow up
  • active infection or documented fever
  • previous antibiotics within 5 days before enrollment

Outcomes

Primary Outcomes

Not specified

Similar Trials